Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
9
×
life sciences
national blog main
biotech
national top stories
san francisco blog main
san francisco top stories
clinical trials
indiana blog main
indiana top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
eli lilly
fda
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston
national
fremanezumab
novartis
teva pharmaceutical
alnylam pharmaceuticals
amgen
avapritinib
blueprint medicines
bristol-myers squibb
calcitonin gene-related peptide
What
approval
9
×
drug
9
×
fda
medicines
new
therapy
won
bio
blueprint
cancer
class
companies
developed
migraine
nod
oral
ret
roundup
therapeutics
treat
address
advanced
agency
ago
aimmune
allergy
alnylam
alnylam’s
amgen
approved
approves
arguments
awarded
bff
big
biogen’s
biopharmaceutical
brexanalone
candidate
candidates
Language
unset
Current search:
drug
×
approval
×
" boston top stories "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines